Literature DB >> 24423227

The PREVENT research programme--a novel research programme to identify and manage midlife risk for dementia: the conceptual framework.

Craig W Ritchie1, Katie Wells, Karen Ritchie.   

Abstract

It is clear that the neurodegenerative disease processes which cause dementias are initiated many years before the onset of symptoms. In people with mild cognitive impairment there is already good evidence available to suggest that many of the key pathologies are well established. The PREVENT research programme seeks to understand the origin point and sequence of pathological changes which lead to dementia. It also aims to determine what clinical, environmental and genetic factors increase (or decrease) the risk of these changes initiating and developing. From this data we will be able to develop risk models that can be applied both in clinical practice and research which illustrate the chances a given individual has of developing clinical symptoms of neurodegenerative disease. Once these risks are identified and the sequence of pathological events are characterized; interventions to remove risk or reduce the impact of a risk can be undertaken, as can studies of agents which specifically target the earliest or most up-stream pathological processes. This paper provides the conceptual framework for the PREVENT programme and other similar studies interrogating people in midlife with a view to providing empirical evidence to inform intervention studies and better clinical practice.

Entities:  

Mesh:

Year:  2013        PMID: 24423227     DOI: 10.3109/09540261.2013.869195

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  7 in total

1.  Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research.

Authors:  Craig W Ritchie; Graciela Muniz Terrera; Terence J Quinn
Journal:  Alzheimers Res Ther       Date:  2015-03-18       Impact factor: 6.982

2.  The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease.

Authors:  José Luis Molinuevo; Nina Gramunt; Juan Domingo Gispert; Karine Fauria; Manel Esteller; Carolina Minguillon; Gonzalo Sánchez-Benavides; Gema Huesa; Sebastián Morán; Rafael Dal-Ré; Jordi Camí
Journal:  Alzheimers Dement (N Y)       Date:  2016-03-03

Review 3.  Participant outcomes and preferences in Alzheimer's disease clinical trials: The electronic Person-Specific Outcome Measure (ePSOM) development program.

Authors:  Stina Saunders; Graciela Muniz-Terrera; Julie Watson; Charlotte L Clarke; Saturnino Luz; Alison R Evans; Craig W Ritchie
Journal:  Alzheimers Dement (N Y)       Date:  2018-12-12

4.  Automated Segmentation of Optical Coherence Tomography Angiography Images: Benchmark Data and Clinically Relevant Metrics.

Authors:  Ylenia Giarratano; Eleonora Bianchi; Calum Gray; Andrew Morris; Tom MacGillivray; Baljean Dhillon; Miguel O Bernabeu
Journal:  Transl Vis Sci Technol       Date:  2020-12-03       Impact factor: 3.283

5.  A national open-access research registry to improve recruitment to clinical studies.

Authors:  Piers Kotting; Adam Smith; Megan B O'Hare; Clarissa Giebel; Lakshini Mendis; Clare Shaw; Imogen Shillito; Martin N Rossor
Journal:  Alzheimers Dement (N Y)       Date:  2021-12-09

6.  Associations between midlife chronic conditions and medication use with anxiety and depression: A cross-sectional analysis of the PREVENT Dementia study.

Authors:  Lucy E Stirland; Sarah Gregory; Tom C Russ; Craig W Ritchie; Graciela Muniz-Terrera
Journal:  J Comorb       Date:  2020-05-05

7.  Macrostructural brain alterations at midlife are connected to cardiovascular and not inherited risk of future dementia: the PREVENT-Dementia study.

Authors:  Maria-Eleni Dounavi; Coco Newton; Natalie Jenkins; Elijah Mak; Audrey Low; Graciela Muniz-Terrera; Guy B Williams; Brian Lawlor; Lorina Naci; Paresh Malhotra; Clare E Mackay; Ivan Koychev; Karen Ritchie; Craig W Ritchie; Li Su; John T O'Brien
Journal:  J Neurol       Date:  2022-03-13       Impact factor: 6.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.